|
PRESS RELEASE
New MHRP pre-clinical SHIV remission study shows progress in delaying viral load rebound
March 1, 2021 - A recent preclinical study by U.S. Military HIV Research Program (MHRP) researchers showed that an experimental therapy combining a TLR7 agonist and two broadly neutralizing antibodies delayed viral rebound in SHIV-infected macaques after antiretroviral therapy (ART) interruption.
The experimental combination therapy consisted of TLR7 agonist GS-986 and two broadly neutralizing antibodies (bnAbs), N6-LS and PGT121, targeting different regions of the HIV envelope. The rhesus macaques were initiated on viral suppressive antiretroviral therapy 14 days post infection, a timespan from infection to treatment which mirrors what is feasible in acute HIV infection. Researchers then administered the experimental combination therapy, followed by ART pause and measured how long it took for SHIV viral load to rebound.
“This study demonstrated that the combination of TLR7 agonist and dual bnAbs delayed viral rebound after ART interruption by 2-fold,” said Dr. Denise Hsu, MHRP Associate Director of Therapeutics. “This approach may represent a potential strategy to target the HIV reservoir in HIV-infected individuals.”
A critical barrier to curing HIV is the reservoir of latent virus that remains hidden and infects cells throughout the body, leading to viral rebound in the vast majority of HIV-infected individuals after they discontinue ART. The hypothesis behind this strategy is that an agent such as the TLR7 agonist, bolstered by therapeutic bnAbs, can stimulate the immune system to clear latent HIV. The paper was published in PLOS Pathogens.
MHRP, part of the Walter Reed Army Institute of Research, collaborates with the Thai Red Cross AIDS Research Centre in Bangkok to identify acutely infected individuals and immediately start them on ART in a study called RV254. For the last few years, small clinical trials within this cohort have evaluated strategies aimed at inducing a cure or long-term remission of HIV. Interventions are wide-ranging and include therapeutic HIV vaccines and broadly neutralizing antibodies.
During these studies, volunteers are taken off ART to test the effects of a candidate intervention. This method, called analytical treatment interruption (ATI), looks at the time it takes for the viral load to rebound after the interruption. Participants are followed closely and restart ART when viral load rises to a certain threshold.
According to Dr. Sandhya Vasan, HJF Director for MHRP, “While we have seen some promise in our ATI trials, it has become clear that we need a combination intervention strategy to generate longer lasting viral suppression.”
Next, the team will analyze imaging data over time, including diffusion imaging data, another type of MRI data that maps the brain's white matter pathways, to further understand how clinical markers of HIV infection affect the brain and the rate of neurodegeneration. As part of that ongoing work, they are inviting researchers around the world to join the ENIGMA-HIV Working Group.
Based on these new preclinical data and building, MHRP hopes to evaluate the combination of innate immune stimulation, active and passive immunization for the induction of HIV remission in early treated people living with HIV.
###
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009339
About MHRP
The U.S. Military HIV Research Program (MHRP), part of the Walter Reed Army Institute of Research, is at the forefront of the battle against HIV/AIDS to protect U.S. troops from infection and reduce the global impact of the disease. MHRP has been recognized as a leader in HIV diagnostics, epidemiology and vaccine research for over three decades and, more recently, has built an international reputation for pioneering discoveries in acute infection and remission. Its research is supported by a cooperative agreement (W81XWH-18-2-0040) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), and the U.S. Department of Defense (DOD). The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army, the Department of Defense, or HJF.
Visit www.hivresearch.org
Contact:
Lisa Reilly
Communications Director | HJF
in support of MHRP and EIDB
Mobile: 301.339.3566
Web: http://www.hivresearch.org
Facebook: http://www.facebook.com/hivresearch
Twitter: http://www.twitter.com/mhrpinfo
The U.S. Military HIV Research Program (MHRP) and the Emerging Infectious Diseases Branch (EIDB) at WRAIR are supported through a cooperative agreement with the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF).
Source: https://www.hivresearch.org/news/press-release/new-mhrp-pre-clinical-shiv-remission-study-shows-progress-delaying-viral-load
"Reproduced with permission - "MHRP"
MHRP
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
|
